Abstract 534P
Background
Lung cancer is a major health concern worldwide. It is the leading cause of cancer-related deaths among both men and women. The current study aims to investigate the role of desmocollin 2 (DSC2) protein in the proliferation, migration, drug resistance and immunotherapy of lung cancer cells. Lung cancer is a major health concern worldwide.
Methods
To examine the role of DSC2 in lung cancer cells, various assays were performed, including CCK-8 and colony formation assays to assess the impact on cell viability and colony formation, respectively. Transwell and wound-healing assays were also conducted to evaluate the impact on cell migration. The flow cytometry double staining assay was employed to detect the apoptosis rate of cells with DSC2 added with cisplatin. Western blotting analysis was used to examine the levels of cell cycle, PI3k/Akt, and apoptosis-related proteins.
Results
The results of this study revealed that DSC2 is upregulated in clinical lung cancer tissues compared to pericarcinomatous tissues and differentially expressed in lung cancer cell lines. The down-regulation of DSC2 in A549 and H358 lung cancer cells significantly reduced cell proliferation, metastasis, and motility. In addition to lung adenocarcinoma cell lines, we also examined its expression in lung squamous cell lines, such as H226. However, the overexpression of DSC2 in H23 and PC9 cell lines showed opposite effects. Western blotting showed that DSC2 could reduce the level of phosphorylated Akt (Ser 473) and p-mTOR. Thus, the study suggested that DSC2 up-regulation promotes proliferation and invasiveness through activation of the PI3K/AKT pathway. DSC2 knockdown can significantly decrease the levels of cyclinB and wee1 protein in A549 and H226. Cisplatin combined with DSC2 knockdown can enhance cell apoptosis rates.
Conclusions
These data suggest that dsc2 promotes the proliferation and migration of lung cancer cells in vitro. Also, the results suggested that dsc2 could affect the cell cycle and apoptosis of lung cells. Furthermore, knockdown of dsc2 could sensitize cisplatin in both lung adenocarcinoma and lung squamous cell lines. Thus, we suggested that dsc2 can be used as a therapeutic target for lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Affiliated Hangzhou First People’s Hospital of Zhejiang university.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract